Evidence map›Paper›PMID 37935567›Full record

ArticleJournal for immunotherapy of cancer2023

Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.

Kunpeng Lv, Mengyao Sun, Hanji Fang, Jieti Wang, Chao Lin, Hao Liu, Heng Zhang, He Li, Hongyong He, Yun Gu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kunpeng LvNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Mengyao SunNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Hanji FangNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jieti WangDepartment of Endoscopy, Fudan University Shanghai Cancer Center, Shanghai, China.
Chao LinDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Hao LiuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Heng ZhangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
He LiDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Hongyong HeDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yun GuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China ygu15@fudan.edu.cn rcli12@fudan.edu.cn fei.shao@shgh.cn jjxufdu@fudan.edu.cn.
Ruochen LiDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China ygu15@fudan.edu.cn rcli12@fudan.edu.cn fei.shao@shgh.cn jjxufdu@fudan.edu.cn.ORCID 0000-0003-4013-3281
Fei ShaoDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China ygu15@fudan.edu.cn rcli12@fudan.edu.cn fei.shao@shgh.cn jjxufdu@fudan.edu.cn.
Jiejie XuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China ygu15@fudan.edu.cn rcli12@fudan.edu.cn fei.shao@shgh.cn jjxufdu@fudan.edu.cn.ORCID 0000-0001-7431-9063
Sun Yat-sen University · CNFudan University · CNShanghai Jiao Tong University · CNFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveImmunotherapy has not yielded satisfactory therapeutic responses in gastric cancer (GC). However, targeting myeloid checkpoints holds promise for expanding the potential of immunotherapy. This study aims to evaluate the critical role of Siglec-10

designSiglec-10

resultsSiglec-10 was predominantly expressed on TAMs in GC, and associated with tumor progression. In Zhongshan Hospital cohort, Siglec-10

conclusionsIn GC, the myeloid checkpoint Siglec-10 contributes to the regulation of immunosuppressive property of TAMs and promotes the depletion of CD8

Indexed as

Stomach NeoplasmsCD8-Positive T-LymphocytesCell DeathHumansRNASialic Acid Binding Immunoglobulin-like LectinsRNASialic Acid Binding Immunoglobulin-like LectinsBiomarkers, TumorImmunotherapyMacrophagesTumor EscapeTumor Microenvironment

Identifiers

PMID37935567
PMCPMC10649907
OpenAlexW4388465601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.